Matricellular proteins as possible biomarkers for early brain injury after aneurysmal subarachnoid hemorrhage

作     者：Hidenori Suzuki Hirofumi Nishikawa Fumihiro Kawakita 

作者机构：Department of NeurosurgeryMie University Graduate School of Medicine 

出 版 物：《Neural Regeneration Research》 (中国神经再生研究（英文版）)

年 卷 期：2018年第13卷第7期

页      面：1175-1178页

核心收录：

学科分类：1002[医学-临床医学] 100204[医学-神经病学] 10[医学] 

基　　金：supported by a Grant-in-Aid for Scientific Research from Novartis Pharmaceuticals to HS 

主　　题：biomarker early brain injury galectin-3 matricellular protein osteopontin periostin subarachnoid hemorrhage tenascin-C 

摘      要：Aneurysmal subarachnoid hemorrhage remains devastating,and the most important determinant of poor outcome is early brain injury（EBI）.In clinical settings,as a surrogate marker of EBI,loss of consciousness at ictus,poor initial clinical grades,and some radiographic findings are used,but these markers are somewhat ***,it is imperative to find biomarkers of EBI that have beneficial prognostic and therapeutic *** our opinion,an ideal biomarker is a molecule that is implicated in the pathogenesis of both EBI and subsequently developing delayed cerebral ischemia（DCI）,being a therapeutic target,and can be measured easily in the peripheral blood in an acute stage.A good candidate of such a biomarker is a matricellular protein,which is a secreted,inducible and multifunctional extracellular matrix *** are many kinds of matricellular proteins reported,but only tenascin-C,osteopontin,galectin-3 and periostin are reported relevant to EBI and *** biomarkers of EBI may stratify aneurysmal subarachnoid hemorrhage patients into categories of risk to develop DCI,and allow objective monitoring of the response to treatment for EBI and earlier diagnosis of *** review emphasizes that further investigation of matricellular proteins as an avenue for biomarker discovery is warranted.